Incidental Detection of Renal Cell Carcinoma is an Independent Prognostic Marker: Results of a Long-Term, Whole Population Study

Pálsdóttir, Helga Björk; Hardarson, Sverrir; Pétursdóttir, Vigdís; Jónsson, Ármann; Jónsson, Eiríkur; Sigurdsson, Martin I.; Einarsson, Guðmundur; Guðbjartsson, Tómas

doi:10.1016/j.juro.2011.09.025

Cited by 59 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Asymptomatic renal tumours were reported to have a favourable independent effect on prognosis in two large case series from Italy and Iceland (Ficarra et al, 2003;Palsdottir et al, 2012). This trend is similarly found in our RCC patients where symptomatic tumours predict shorter survival.…”

Section: Discussionsupporting

confidence: 84%

Clinical Prognostic Factors and Survival Outcome in Renal Cell Carcinoma Patients - A Malaysian Single Centre Perspective

Yap¹,

Ng²,

Ong³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 84%

Clinical Prognostic Factors and Survival Outcome in Renal Cell Carcinoma Patients - A Malaysian Single Centre Perspective

Yap¹,

Ng²,

Ong³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…CCRCC is by far the most common renal cancer histological variant, accounting for 75 to 80% of renal neoplasms in adults 7 . CCRCC is a clinically aggressive neoplasm, where radical surgery is the only treatment with significant impact on patient survival 8 . Chemo- and radiotherapy are inefficient so far and modern targeted therapies obtain only partial results 9 .…”

Section: The Contextmentioning

confidence: 99%

A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma

López

Cortés

2016

F1000Res

View full text Add to dashboard Cite

Intratumor heterogeneity (ITH) is an inherent process in cancer development which follows for most of the cases a branched pattern of evolution, with different cell clones evolving independently in space and time across different areas of the same tumor. The determination of ITH (in both spatial and temporal domains) is nowadays critical to enhance patient treatment and prognosis. Clear cell renal cell carcinoma (CCRCC) provides a good example of ITH. Sometimes the tumor is too big to be totally analyzed for ITH detection and pathologists decide which parts must be sampled for the analysis. For such a purpose, pathologists follow internationally accepted protocols. In light of the latest findings, however, current sampling protocols seem to be insufficient for detecting ITH with significant reliability. The arrival of new targeted therapies, some of them providing promising alternatives to improve patient survival, pushes the pathologist to obtain a truly representative sampling of tumor diversity in routine practice. How large this sampling must be and how this must be performed are unanswered questions so far. Here we present a very simple method for tumor sampling that enhances ITH detection without increasing costs. This method follows a divide-and-conquer (DAC) strategy, that is, rather than sampling a small number of large-size tumor-pieces as the routine protocol (RP) advises, we suggest sampling many small-size pieces along the tumor. We performed a computational modeling approach to show that the usefulness of the DAC strategy is twofold: first, we show that DAC outperforms RP with similar laboratory costs, and second, DAC is capable of performing similar to total tumor sampling (TTS) but, very remarkably, at a much lower cost. We thus provide new light to push forward a shift in the paradigm about how pathologists should sample tumors for achieving efficient ITH detection.

show abstract

“…Vimentin is considered as a potential molecular target for cancer therapy but its specific role remains unclear as well [4,27]. Moreover, vimentin is used as a reliable biomarker in differentiating certain types of renal cell carcinomas [32]. It has been shown that vimentin is expressed in the majority of clear cell and papillary renal cell carcinomas; however, it is rarely expressed in oncocytoma and chromophobe renal cell carcinomas [32,33].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, vimentin is used as a reliable biomarker in differentiating certain types of renal cell carcinomas [32]. It has been shown that vimentin is expressed in the majority of clear cell and papillary renal cell carcinomas; however, it is rarely expressed in oncocytoma and chromophobe renal cell carcinomas [32,33]. Therefore, vimentin may assist in confirming diagnoses and having a prognostic value regarding each subtype of RCC.…”

Section: Introductionmentioning

confidence: 99%

Biomarkers Role in Prognosis and Survival Outcomes in Patients with Renal Tumors: Review Article

Mohamed¹

2017

UNOAJ

View full text Add to dashboard Cite

Incidental Detection of Renal Cell Carcinoma is an Independent Prognostic Marker: Results of a Long-Term, Whole Population Study

Cited by 59 publications

References 27 publications

Clinical Prognostic Factors and Survival Outcome in Renal Cell Carcinoma Patients - A Malaysian Single Centre Perspective

Clinical Prognostic Factors and Survival Outcome in Renal Cell Carcinoma Patients - A Malaysian Single Centre Perspective

A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma

Biomarkers Role in Prognosis and Survival Outcomes in Patients with Renal Tumors: Review Article

Contact Info

Product

Resources

About